{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:29:11Z","timestamp":1765960151473,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Familial clustering of lymphoid and\/or hematological malignancies (FHM) provides an opportunity to study the responsible genes. The data is limited in patients with lymphoid and hematological malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The lymphoma database was used to identify patients seen in our institution from 1998 to 2019 with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). We studied FHM by collecting detailed history of any malignancy in the family (FM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two hundred NLPHL patients were identified. Contacting was not possible in 30 patients due to no response to the phone calls (22) and death [1]. 170\/200 patients were interviewed; represented 167 families (3 patients with a family member with NLPHL). These 170 patients provided information about 8225 family members. These 167 families had a total of 329 family members with 334 malignancies (including 167 NLPHL patients and 5 members with 2 malignancies each). Of these 167 patients, 77 (46.1%) had no FM while 90 (53.9%) patients had a positive FM; 162 family members with 167 malignancies. Among these 167 families, 31 families (18.6%) had members with FHM +\/\u2212 solid cancers. These 31 families had 35 family members (25 males:10 females) with 16 lymphomas: diffuse large B cell lymphoma [2], follicular center cell lymphoma [3], chronic lymphocytic leukemia\/small lymphocytic lymphoma [3], non-Hodgkin lymphoma [2], classical HL [2], and NLPHL [4]. Total of 8 leukemia: acute lymphoblastic leukemia [4], acute myeloid leukemia [3], and leukemia - no subtyping [5]. These 35 FHM members are 1st [6], 2nd (16), and 3rd [7] degree relatives of 31 NLPHL patients. There are 4 families with NLPHL in family members; all these 8 NLPHL patients are male and are alive. The median total number of 1st\u2009+\u20092nd +3rd degree members are 81. The decrease in the age of diagnosis from 1st generation to the 2nd generation (anticipation) was noted in 13\/17 patients; 2nd generation median age at diagnosis was 29.7\u2009years vs 1st generation age 53\u2009years (developed malignancy 23.3\u2009years earlier).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>FHM is frequent in NLPHL. This study provided us many important insights for planning future studies in terms of interviewing technique, time, and resource allocation and genetic testing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-021-00175-0","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T11:10:35Z","timestamp":1612869035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-0944","authenticated-orcid":false,"given":"Saad","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Shahzad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Al-Kofide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Elshenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Hassan","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"issue":"3","key":"175_CR1","first-page":"431","volume":"25","author":"V J\u00f8nsson","year":"2011","unstructured":"J\u00f8nsson V, Awan H, Nyquist E, Maisenh\u00f8lder M, Johannesen TB, Ly B, et al. Familial Hodgkin's lymphoma in Scandinavia. In Vivo. 2011;25(3):431\u20137.","journal-title":"In Vivo"},{"issue":"3","key":"175_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07355.x","volume":"143","author":"JR Brown","year":"2008","unstructured":"Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, et al. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008;143(3):361\u20138.","journal-title":"Br J Haematol"},{"issue":"6","key":"175_CR3","first-page":"1233","volume":"72","author":"GG Giles","year":"1984","unstructured":"Giles GG, Lickiss JN, Baikie MJ, Lowenthal RM, Panton J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst. 1984;72(6):1233\u201340.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"175_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cyto.b.10013","volume":"52","author":"GE Marti","year":"2003","unstructured":"Marti GE, Carter P, Abbasi F, Washington GC, Jain N, Zenger VE, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2003;52(1):1\u201312.","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"175_CR5","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/cncr.20189","volume":"100","author":"LR Goldin","year":"2004","unstructured":"Goldin LR, Pfeiffer RM, Gridley G, Gail MH, Li X, Mellemkjaer L, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100(9):1902\u20138.","journal-title":"Cancer."},{"issue":"8","key":"175_CR6","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2006-06-031948","volume":"109","author":"SS Wang","year":"2007","unstructured":"Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the international lymphoma epidemiology consortium (InterLymph). Blood. 2007;109(8):3479\u201388.","journal-title":"Blood."},{"issue":"2","key":"175_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1053\/j.seminoncol.2006.01.013","volume":"33","author":"GS Sellick","year":"2006","unstructured":"Sellick GS, Catovsky D, Houlston RS. Familial chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):195\u2013201.","journal-title":"Semin Oncol"},{"issue":"19","key":"175_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jnci\/dji293","volume":"97","author":"ET Chang","year":"2005","unstructured":"Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G, Glimelius B, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst. 2005;97(19):1466\u201374.","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"175_CR9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","volume":"126","author":"E Kharazmi","year":"2015","unstructured":"Kharazmi E, Fallah M, Pukkala E, Olsen JH, Tryggvadottir L, Sundquist K, et al. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries. Blood. 2015;126(17):1990\u20135.","journal-title":"Blood."},{"issue":"3","key":"175_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/10428190310001602354","volume":"45","author":"GN Campbell","year":"2004","unstructured":"Campbell GN, Lloyd J, Wotherspoon A, Coulter C, Bain BJ. Nodular lymphocyte predominant Hodgkin lymphoma in siblings. Leuk Lymphoma. 2004;45(3):609\u201311.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"175_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2141.2005.05672.x","volume":"130","author":"F Bauduer","year":"2005","unstructured":"Bauduer F, Vassallo J, Delsol G, Brousset P. Clustering and anticipation for nodular lymphocyte predominance Hodgkin lymphoma within a French Basque kindred. Br J Haematol. 2005;130(4):648\u20139.","journal-title":"Br J Haematol"},{"issue":"11","key":"175_CR12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/10428190500236502","volume":"46","author":"A Unal","year":"2005","unstructured":"Unal A, Sari I, Deniz K, Ozkan M, Kontas O, Eser B, et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: successful treatment with CHOP plus rituximab. Leuk Lymphoma. 2005;46(11):1613\u20137.","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"175_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1200\/JCO.2012.43.5958","volume":"31","author":"S Saarinen","year":"2013","unstructured":"Saarinen S, Pukkala E, Vahteristo P, M\u00e4kinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013;31(7):938\u201343.","journal-title":"J Clin Oncol"},{"issue":"8","key":"175_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.23482","volume":"88","author":"M Merli","year":"2013","unstructured":"Merli M, Maffioli M, Ferrario A, Passamonti F. Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma. Am J Hematol. 2013;88(8):719\u201320.","journal-title":"Am J Hematol"},{"issue":"1","key":"175_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/djj005","volume":"98","author":"ET Chang","year":"2006","unstructured":"Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst. 2006;98(1):61\u20138.","journal-title":"J Natl Cancer Inst"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13053-021-00175-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T11:19:34Z","timestamp":1612869574000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-021-00175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1186\/s13053-021-00175-0","relation":{},"ISSN":["1897-4287"],"issn-type":[{"type":"electronic","value":"1897-4287"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approved by Institutional \u201cResearch Advisory Council (RAC)\u201d. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia. RAC project # 2021\u2013048 lymphoma database. Waiver of signed consent as per RAC (no individual patient identified data \/ no pictures \/ verbal consent documented on paper or electronic chart). This waiver of signed consent was for participation in the database collection study and subsequent publications as per RAC guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Approved by Institutional Research Advisory Counsel for publication","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None - Authors declare no conflict of interest","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}